Aethlon Medical(AEMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AEMD Aethlon Medical

Closed 11-25 16:00:00 EST

0.4032

-0.0011

-0.27%

盘后0.4144

+0.0112+2.78%

19:16 EST

High0.4147	Low0.3919	Vol130.71K
Open0.3940	D1 Closing0.4043	Amplitude5.64%
Mkt Cap5.62M	Tradable Cap5.58M	Total Shares13.94M
T/O52.07K	T/O Rate0.94%	Tradable Shares13.84M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"AEMD","market":"US","secType":"STK","nameCN":"Aethlon Medical","latestPrice":0.4032,"timestamp":1732568400000,"preClose":0.4043,"halted":0,"volume":130706,"hourTrading":{"tag":"盘后","latestPrice":0.4144,"preClose":0.4032,"latestTime":"19:16 EST","volume":3968,"amount":1627.4665,"timestamp":1732580163576},"delay":0,"floatShares":13837392,"shares":13937327,"eps":-1.696862,"marketStatus":"Closed","change":-0.0011,"latestTime":"11-25 16:00:00 EST","open":0.394,"high":0.4147,"low":0.39191,"amount":52071.19478872,"amplitude":0.056369,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.696862,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732611600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.4043,"preHourTrading":{"tag":"盘前","latestPrice":0.4,"preClose":0.4043,"latestTime":"09:29 EST","volume":1961,"amount":785.47331413,"timestamp":1732544999140},"postHourTrading":{"tag":"盘后","latestPrice":0.4144,"preClose":0.4032,"latestTime":"19:16 EST","volume":3968,"amount":1627.4665,"timestamp":1732580163576},"volumeRatio":0.474754,"impliedVol":3.8125,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/AEMD/wiki","defaultTab":"wiki","newsList":[{"id":"2483320455","title":"Maxim Group Sticks to Their Hold Rating for Aethlon Medical (AEMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483320455","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483320455?lang=en_us&edition=fundamental","pubTime":"2024-11-15 20:35","pubTimestamp":1731674152,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Anthony Vendetti maintained a Hold rating on Aethlon Medical (AEMD – Research Report) yesterday. The company’s shares closed ye...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-hold-rating-for-aethlon-medical-aemd-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-hold-rating-for-aethlon-medical-aemd-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AEMD"],"gpt_icon":0},{"id":"2483192322","title":"Aethlon Medical Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483192322","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483192322?lang=en_us&edition=fundamental","pubTime":"2024-11-15 20:12","pubTimestamp":1731672720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AEMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 15, 2024 07:12 ET (12:12 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEMD"],"gpt_icon":0},{"id":"2483884313","title":"Aethlon’s Future at Risk: Financial Struggles, Stockholder Dilution, and Market Challenges Loom","url":"https://stock-news.laohu8.com/highlight/detail?id=2483884313","media":"TIPRANKS","labels":["Economic Data"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483884313?lang=en_us&edition=fundamental","pubTime":"2024-11-15 14:02","pubTimestamp":1731650525,"startTime":"0","endTime":"0","summary":"Aethlon (AEMD) has disclosed a new risk, in the Accounting & Financial Operations category. Aethlon faces significant financial and operational ris...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aethlons-future-at-risk-financial-struggles-stockholder-dilution-and-market-challenges-loom?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aethlons-future-at-risk-financial-struggles-stockholder-dilution-and-market-challenges-loom?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"Economic Data","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AEMD","BK4583","BK4568","BK4082"],"gpt_icon":0},{"id":"2483336682","title":"AEMD: Oncology Trial Moves Forward as Patient Enrollments Begin, Positive on Cost Containment Measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2483336682","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483336682?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:09","pubTimestamp":1731593340,"startTime":"0","endTime":"0","summary":"Patient enrollments begin for AEMD’s basket oncology trial. Aethlon Medical  announced FY 2Q results and provided a business update yesterday. The company has made significant strides in moving its clinical activities forward over the past few weeks. The company has enrolled the first two patients in its oncology trial  at the Royal Adelaide Hospital in Australia. Another site that will participate in the study, Pindara Private Hospital in Australia, has also received ethics committee approval and training on the Aethlon Hemopurifier and is now initiating patient enrollment. The company has also trained staff at a third hospital in Australia and expects this facility to receive formal ethics committee approval in the near-term and begin patient enrollments. Overall, we present our key takeaways in this note.Lead asset the Aethlon Hemopurifier is being evaluated in combination with checkpoint inhibitors as a potential treatment for patients suffering from various solid tumor types. With","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aemd-oncology-trial-moves-forward-140900065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FORD","BK4568","BK4082","AEMD","BK4202","BK4583"],"gpt_icon":0},{"id":"2483887749","title":"Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally","url":"https://stock-news.laohu8.com/highlight/detail?id=2483887749","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483887749?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589200,"startTime":"0","endTime":"0","summary":"Vancouver, Kelowna, and Delta, British Columbia-- - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases a snapshot looking at the advancement of treatments for solid tumors as global cancer incidence rates rise, featuring Aethlon Medical, Inc. , a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.Looking at the harsh reality of the rise of cancer globally, the BBC reported earlier this year, \"One study found that the global incidence of early-onset cancer had increased by 79% between 1990 and 2019, with the number of cancer-related deaths in younger people rising by 29%. Another report in The Lancet Public Health described how cancer incidence rates in the US have steadily risen between the generations across 17 different cancers, particularly in Generation Xers and Millennials.\". Yesterday, Aethlon Medical, Inc.  reported financial results for its fiscal second quarter e","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/yvTTJD_651JhC3eRbd.HuQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/f6dccb4b99c4df8559d8017528792388","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/yvTTJD_651JhC3eRbd.HuQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/f6dccb4b99c4df8559d8017528792388"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biotech-medical-tech-stocks-report-130000783.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-medical-tech-stocks-report-130000783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","AEMD","BK4022","IE00BZ199S13.USD","LU0124384867.USD","BK4568","BK4585","IE00B7SZL793.SGD","LU1720051108.HKD","BK4231","LU1720051017.SGD","SITC","BK4080","IE00B66KJ199.SGD","CTOS","LU1548497426.USD","LU0348723411.USD","BK4159","BK4141","BK4583","BK4006","IE0031619046.USD","LU2298322129.HKD","LU1861214812.USD","LU2360107325.USD","CAGR","LU1978683503.SGD","LU1861220033.SGD","BK4230","BK4588","LU1861219969.SGD","LU1854103824.USD","ON","CRS","IE00B19Z4B17.USD","LU2357305700.SGD","LU1861215975.USD","CAR","LU0724618433.USD","IE00BD6J9T35.USD","LU1854104046.USD","BK4512","BK4104"],"gpt_icon":1},{"id":"2483841979","title":"Aethlon Medical Inc (AEMD) Q2 2025 Earnings Call Highlights: Progress in Oncology Trials and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2483841979","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483841979?lang=en_us&edition=fundamental","pubTime":"2024-11-14 15:14","pubTimestamp":1731568451,"startTime":"0","endTime":"0","summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.Aethlon Medical Inc  has made significant progress in its oncology trial efforts in Australia, enrolling the first two patients and opening a second hospital for patient enrollment.The company has successfully reduced its operating expenses by approximately $300,000, primarily through a decrease in professional fees.The company holds a cash balance of approximately $6.9 million, providing a solid financial foundation for ongoing research and development.There was an increase of approximately $200,000 in payroll and related expenses, largely due to separation expenses following an executive termination and workforce reduction.General and administrative expenses increased by $100,000, mainly due to costs related to the ongoing oncology clinical trial.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZzEg8dYXtXKoZ2QCPcz6MQ--~B/aD0xODA7dz0xODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/a40ced4714fddaddbb23f16db7f4e666","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZzEg8dYXtXKoZ2QCPcz6MQ--~B/aD0xODA7dz0xODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/a40ced4714fddaddbb23f16db7f4e666"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aethlon-medical-inc-aemd-q2-071411387.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PRGS","AEMD"],"gpt_icon":0},{"id":"2483189467","title":"Aethlon Medical Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483189467","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483189467?lang=en_us&edition=fundamental","pubTime":"2024-11-14 11:54","pubTimestamp":1731556442,"startTime":"0","endTime":"0","summary":"* Aethlon Medical Inc    reported a quarterly adjusted loss of 20 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.22.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEMD"],"gpt_icon":0},{"id":"2483759865","title":"Aethlon Medical Advances Oncology Trials and Global Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2483759865","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483759865?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:54","pubTimestamp":1731534899,"startTime":"0","endTime":"0","summary":"Aethlon Medical ( ($AEMD) ) just unveiled an update. Aethlon Medical, Inc. has reported significant advancements in its oncology trials, enrolling ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aethlon-medical-advances-oncology-trials-and-global-expansion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aethlon-medical-advances-oncology-trials-and-global-expansion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4583","BK4568","BK4082","AEMD"],"gpt_icon":0},{"id":"2483659748","title":"Aethlon Medical Q2 2025 GAAP EPS $(0.20), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2483659748","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483659748?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:53","pubTimestamp":1731534804,"startTime":"0","endTime":"0","summary":"Aethlon Medical (NASDAQ:AEMD) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. This is a 83.61 percent increase over losses of $(1.22) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41956762/aethlon-medical-q2-2025-gaap-eps-0-20-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Aethlon Medical Q2 2025 GAAP EPS $(0.20), Inline","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEMD"],"gpt_icon":0},{"id":"2483086878","title":"Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483086878","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483086878?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:15","pubTimestamp":1731532504,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA1NGZQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","AEMD","BK4082","BK4583"],"gpt_icon":0},{"id":"2483658008","title":"Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483658008","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483658008?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:15","pubTimestamp":1731532500,"startTime":"0","endTime":"0","summary":"Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies. Two Australian Sites Open For Patient Enrollment in Hemopurifier Cancer Trial. SAN DIEGO, Nov. 13, 2024 /PRNewswire/ -- Aethlon Medical, Inc. , a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2024 and provided an update on recent developments.During the second quarter, and subsequently, the company advanced its oncology trial efforts in Australia, while implementing cost-cutting measures to streamline operations. Management is pleased to report positive progress on these initiatives, specifically:. Clinical Trials: The first two patients have now been enrolled at the Royal Adelaide Hospital in Adelaide, Australia. Additionally, Pi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xP9CteM8zMY0_9pwo97hUg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/595e59be0e7283e22cffb3f1ff640cb9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xP9CteM8zMY0_9pwo97hUg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/595e59be0e7283e22cffb3f1ff640cb9"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/aethlon-medical-announces-financial-results-211500908.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aethlon-medical-announces-financial-results-211500908.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","BK4568","AEMD","BK4583","IDE"],"gpt_icon":0},{"id":"2482088796","title":"Innovative Medical Technology Advances with First Patient Enrollments","url":"https://stock-news.laohu8.com/highlight/detail?id=2482088796","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482088796?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:00","pubTimestamp":1731416400,"startTime":"0","endTime":"0","summary":"Vancouver, Kelowna, and Delta, British Columbia-- - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at the future of medical technology as first patients are enrolled in potential breakthrough trials, featuring Aethlon Medical, Inc. , a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.According to Statista.com, \"The Medical Technology market, which encompasses various markets, including Medical Devices, is anticipated to witness significant revenue growth in the coming years.\". \"By 2024, the market is projected to reach a staggering US$597.00bn worldwide. Among these markets, Medical Devices are expected to dominate, with a projected market volume of US$508.00bn by 2024. Furthermore, the Medical Technology market is expected to demonstrate a steady annual growth rate of 5.29% from 2024 to 2029.\". \"Enrollment of the first patient represents the achievement of a critical milestone for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/innovative-medical-technology-advances-first-130000009.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/innovative-medical-technology-advances-first-130000009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4583","BK4082","AEMD","IDE","BK4568"],"gpt_icon":1},{"id":"2482771493","title":"Aethlon Medical Inc  expected to post a loss of 19 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482771493","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482771493?lang=en_us&edition=fundamental","pubTime":"2024-11-12 11:45","pubTimestamp":1731383117,"startTime":"0","endTime":"0","summary":"Aethlon Medical Inc  expected to post a loss of19cents a share - Earnings Preview Aethlon Medical Inc AEMD.OQ AEMD.O is expected to show no change in quarterly revenue when it reports  results on Nove","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nL8N3MJ05Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEMD"],"gpt_icon":0},{"id":"2482784514","title":"Aethlon Medical Enrolls First Patient in Hemopurifier Trial -- Shares Up 14% Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2482784514","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482784514?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:41","pubTimestamp":1731332507,"startTime":"0","endTime":"0","summary":"Aethlon Medical  said Monday that the first patient has been enrolled in an Australian clinical trial of its immunotherapeutic device Hemopurifier to treat patients with solid tumors.The company said the trial will treat patients who have stable or progressive disease while receiving anti-PD-1 monotherapy, such as Keytruda or Opdivo.Aethlon said the first patient will receive anti-PD-1 therapy within the next two months, when concentrations of extracellular vesicles and anti-tumor T cell activity will be measured.Shares of Aethlon Medical were up 14% in recent premarket activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AEMD","BK4082","BK4583","BK4568"],"gpt_icon":0},{"id":"2482867027","title":"BRIEF-Aethlon Medical Reaches Key Milestone With Enrollment Of The First Patient In (FPI) Its Hemopurifier Cancer Trial In Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2482867027","media":"Reuters","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482867027?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:03","pubTimestamp":1731330210,"startTime":"0","endTime":"0","summary":"Nov 11 (Reuters) - Aethlon Medical Inc   :   * AETHLON MEDICAL REACHES KEY MILESTONE WITH ENROLLMENT OF THE FIRST PATIENT IN (FPI) ITS HEMOPURIFIER® CANCER TRIAL IN AUSTRALIASource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4234","BK4583","FPI","BK4568","AEMD","BK4084","BK4082"],"gpt_icon":0},{"id":"2482078612","title":"Aethlon Medical Reaches Key Milestone With Enrollment of the First Patient in (Fpi) Its Hemopurifier® Cancer Trial in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2482078612","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482078612?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:01","pubTimestamp":1731330062,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUA6BNFSX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AEMD","BK4583","BK4082","BK4568"],"gpt_icon":0},{"id":"2482568784","title":"Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2482568784","media":"PR Newswire","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482568784?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:01","pubTimestamp":1731330060,"startTime":"0","endTime":"0","summary":"Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital. Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies. SAN DIEGO, Nov. 11, 2024 /PRNewswire/ --Aethlon Medical, Inc. , a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced enrollment of the first patient in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda  or Opdivo  . The patient was enrolled on October 29, 2024, by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital in Australia.The primary endpoint of the approximately nine to 18-patient, safety, feasibility and dose-finding trial is the incidence of adverse even","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TTjt9CEe6z.ooowceAOYKA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/a6584df642cfb775c4e0f54ac1290019","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TTjt9CEe6z.ooowceAOYKA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/a6584df642cfb775c4e0f54ac1290019"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/aethlon-medical-reaches-key-milestone-130100832.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aethlon-medical-reaches-key-milestone-130100832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4234","AEMD","BK4583","FPI","BK4568","BK4082","BK4084","IDE"],"gpt_icon":0},{"id":"2481061646","title":"Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481061646","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481061646?lang=en_us&edition=fundamental","pubTime":"2024-11-06 21:01","pubTimestamp":1730898060,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov. 6, 2024 /PRNewswire/ -- Aethlon Medical, Inc. , a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal second quarter ended September 30, 2024, at 4:15 p.m. ET on Wednesday, November 13, 2024.Interested parties without internet access or unable to pre-register may dial in by calling:. PARTICIPANT DIAL IN : 1-844-836-8741PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442. All callers should ask for the Aethlon Medical, Inc. conference call.A replay of the call will be available approximately one hour after the end of the call through December 13, 2024. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529  or 1-412-317-0088  or Canada toll free at 1-855-669-9658. The replay conference ID number is 1920733.Forward Looking StatementsThis press release contains forward-looking statements within the meaning of Sect","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/C9.ElEoE6TzNDijC6DZTCw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/18be20015a562c42dea5e434bb57d5d0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/C9.ElEoE6TzNDijC6DZTCw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/18be20015a562c42dea5e434bb57d5d0"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/aethlon-medical-release-fiscal-second-130100732.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aethlon-medical-release-fiscal-second-130100732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","BK4181","BK4588","BK4583","AEMD","BK4218","IDE","HST","BK4585","BK4082"],"gpt_icon":0},{"id":"2479047769","title":"Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2479047769","media":"GlobeNewswire","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479047769?lang=en_us&edition=fundamental","pubTime":"2024-10-29 19:00","pubTimestamp":1730199600,"startTime":"0","endTime":"0","summary":"MIAMI, Oct. 29, 2024  -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 76th Emerging Growth Conference on October 30 & 31, 2024.The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ldm8wneYHS9yfU2ej3bTbA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c4f5f7fb74321f8cf4d35709ef806d49","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ldm8wneYHS9yfU2ej3bTbA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c4f5f7fb74321f8cf4d35709ef806d49"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/presenting-emerging-growth-conference-76-110000392.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QID","BK4568","PLGGF","BK4505","BIXT","ASPI","PGEZF","GOSS","BK4023","BK4196","PSQ","BK4135","BK4188",".IXIC","STXPF","VIOT","VOXR","BK4179","BK4077","CIA","LDTCW","MNQmain","XBOTF","BK4139","IMC.AU","BK4021","EUDAW","BK4191","BVAXF","BK4162","NCSM","ICON","GIFT","QLD","SIGY","TQQQ","BNRG","MNMRF","BK4082","IMRN","SQQQ","NQmain","AEMD","ELMGF","NRXBF","SEVCF","EUDA","VANI","LDTC","BK4583"],"gpt_icon":1},{"id":"2478957409","title":"OTC Markets Hosts Virtual Investor Presentation with Jim Frakes, Interim CEO & CFO, and Steven LaRosa, MD, Chief Medical Officer, of Aethlon Medical Inc., with Marla Marin, Senior Analyst at Zacks SCR","url":"https://stock-news.laohu8.com/highlight/detail?id=2478957409","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478957409?lang=en_us&edition=fundamental","pubTime":"2024-10-25 21:07","pubTimestamp":1729861620,"startTime":"0","endTime":"0","summary":"Anthony Krause: Hello and welcome to Virtual Investor Conferences. My name is Anthony Krause, and on behalf of OTC Markets and our co-host, Zacks Small Cap Research, we're very pleased you have joined us for our next live presentation from Aethlon Medical. Their session will be moderated by Marla Marin, senior Analyst at Zacks Small Cap Research. Please note that you can submit questions for the presenter in the box to the left of the slides. You can also view a company's availability for one-on-one meetings through the Schedule Meetings tab on the conference platform. At this point, I'm very pleased to welcome Jim Frakes, interim CEO and CFO, and Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical Inc., Which trades on NASDAQ under the symbol AEMD. Welcome, Jim, Steven, and Marla.Marla Marin: Thank you. Hi, Jim. Hi, Steve. Thanks for making time for this. Let's start by getting a little bit of information about the basics. What is the Hemopurifier?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/otc-markets-hosts-virtual-investor-130700778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4533","IE00BLSP4239.USD","LU0265550946.USD","LU0203345920.USD","LU0861579265.USD","LU1037948541.HKD","AEMD","BK4585","IE0009355771.USD","MD","BK4007","IE00B2B36J28.USD","LU1066051225.USD","LU1093756168.USD","LU1941712264.USD","IE00BN8TJ469.HKD","LU1066051498.USD","IE00BLSP4452.SGD","IE00B1BXHZ80.USD","LU0965509283.SGD","LU1585245621.USD","MRIN","LU1917777945.USD","BK4568","LU1057294990.SGD","LU1934455194.USD","LU1934455277.USD","LU0211331839.USD","BK4588","IE00BJJMRZ35.SGD","LU0985320562.USD","LU1061106388.HKD","IE0002141913.USD","LU1066051811.HKD","LU0058720904.USD","LU0006306889.USD","BK4559","IE00B4R5TH58.HKD","LU0122379950.USD","IE00BBT3K403.USD","LU1023059063.AUD","BK4196","BK4082","BK4550","MRK","LU0965508806.USD","IE00BJT1NW94.SGD","LU1934455863.HKD","LU1291159041.SGD","IE00BFTCPJ56.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aethlonmedical.com","stockEarnings":[{"period":"1week","weight":0.0125},{"period":"1month","weight":0.0225},{"period":"3month","weight":-0.3263},{"period":"6month","weight":-0.0374},{"period":"1year","weight":-0.7608},{"period":"ytd","weight":-0.8154}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.471639},{"month":2,"riseRate":0.111111,"avgChangeRate":-0.149923},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.101527},{"month":4,"riseRate":0.111111,"avgChangeRate":-0.123823},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.137562},{"month":6,"riseRate":0.888889,"avgChangeRate":0.28379},{"month":7,"riseRate":0.222222,"avgChangeRate":-0.094145},{"month":8,"riseRate":0.2,"avgChangeRate":-0.128305},{"month":9,"riseRate":0.4,"avgChangeRate":-0.032528},{"month":10,"riseRate":0.2,"avgChangeRate":-0.092625},{"month":11,"riseRate":0.5,"avgChangeRate":0.01199},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.057891}],"exchange":"NASDAQ","name":"Aethlon Medical","nameEN":"Aethlon Medical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aethlon Medical(AEMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aethlon Medical(AEMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aethlon Medical,AEMD,Aethlon Medical股票,Aethlon Medical股票老虎,Aethlon Medical股票老虎国际,Aethlon Medical行情,Aethlon Medical股票行情,Aethlon Medical股价,Aethlon Medical股市,Aethlon Medical股票价格,Aethlon Medical股票交易,Aethlon Medical股票购买,Aethlon Medical股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aethlon Medical(AEMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aethlon Medical(AEMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}